Duff & Phelps Provided a Fairness Opinion to the Board of Directors of Chiasma, Inc. on Its Sale to Amryt Pharma plc

or to bookmark this page

Click here to bookmark this page

Click here to remove bookmark

has signed a definitive merger agreement to be acquired by

Contact Us

On May 4, 2021, Chiasma, Inc. (NASDAQ: CHMA), a Newton, Massachusetts-based biopharmaceutical company, signed a definitive merger agreement to be acquired by Amryt Pharma plc (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, in an all-stock deal.

Duff & Phelps, A Kroll Business, served as a financial advisor to the board of directors of Chiasma and provided an independent fairness opinion in connection with the transaction.

About Chiasma, Inc. (NASDAQ: CHMA)
Chiasma is a commercial stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. Goodwin Procter LLP served as legal counsel to Chiasma.

About Amryt Pharma plc (NASDAQ: AMYT, AIM: AMYT)
Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets. Gibson, Dunn & Crutcher LLP served as legal counsel to Amryt.

2021-05-10T00:00:00.0000000 /-/media/assets/images/transactions/2021/chiasma-inc.png /-/media/assets/images/transactions/2021/amryt-pharma.png /about-us/transactions/fairness-opinions/fairness-opinion-chiasma-inc case study {6B6F3B01-98A6-4BC2-B2CD-CBD127447FB5} {A7EB9162-FD06-4A2C-9E52-7BE04F16488F} {5CE144D0-ADDC-43A3-95E4-3428CA819BF8} {4DACD310-421A-42AC-BEF4-8AA7E70484CD} {49ED5FA4-1B37-4C7A-8D38-6861240EC2CC} {D3AE3EC6-3254-4441-B111-1AF8D558906C} {B871D4F9-5FCB-40B9-8710-871A30B710AB}

Other Areas We Can Help

M&A Advisory

Middle-market M&A advisory differentiated by industry expertise and superior deal execution.

M&A Advisory

Comprehensive Due Diligence Solution

Comprehensive diligence support primarily in the areas of tax, compliance and regulatory, operations, financial and accounting, investigations and disputes and cyber/IT risk.

Comprehensive Due Diligence Solution

Transaction Advisory Services

Seamless analytical advisory through the deal continuum, from transaction origination to closing.

Transaction Advisory Services

Related Case Studies

Insights

M&A Advisory

Restaurant Sector Update – Spring 2021

M&A Advisory
M&A Advisory

Healthcare Services Sector Update – April 2021

M&A Advisory
M&A Advisory

Food and Beverage M&A Landscape – Spring 2021

M&A Advisory
M&A Advisory

Global Software Sector Update – Spring 2021

M&A Advisory

News